MedTrace Logo

the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure

NCT03333499 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2017-11-28

No results posted yet for this study

Summary

The investigators set out to evaluate the effects of the traditional Chinese medicinal mixture under the brand name YangXinShi (YXS) on the prognosis in patients with chronic heart failure when it is combined with the optimal combination drug treatment of heart failure.

Conditions

Interventions

DRUG

YanXinShi placebo pills

participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure

DRUG

YanXinShi pills

participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure

DRUG

Trimetazidine pills

participants will take 20mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure

DRUG

YanXinShi and Trimetazidine pills

participants will take 1800 mg YXS and 20 mg Trimetazidine pills TID in addition to the optimal combination drug treatment of heart failure

Sponsors & Collaborators

  • Dalian University

    lead OTHER

Principal Investigators

  • qin yu, M.D., Ph.D. · Affiliated Zhongshan Hospital of Dalian University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03333499 on ClinicalTrials.gov